Rheonix
Company

Last deal

Amount

Convertible Note

Stage

13.02.2019

Date

11

all rounds

$86.7M

Total amount

General

About Company
Rheonix develops automated molecular testing solutions for various applications.

Industry

Sector :

Subsector :

founded date

01.01.2007

Number of employees

Company Type

For Profit

Last funding type

Convertible Note

IPO status

Private

Description

The New York-based biomedical device company, Rheonix, offers a range of products and technology for human/veterinary in vitro diagnostics, food/water testing, SNP analysis for personalized medicine applications, and more. Their Encompass platform is a highly customizable technology that performs fully automated, complex molecular assays in an easy-to-use and affordable format on the Rheonix CARD cartridge. The company is committed to making molecular diagnostics available to more people, in more places, more often, and is well-positioned to penetrate key molecular diagnostic market sectors.
Contacts

Social url